Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
Robinson
Joan L
JL
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002170:Canada; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000502:physiology; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000151:congenital / Q000175:diagnosis / Q000191:economics / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000191:economics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab